Natera announced enrollment of first patients in a randomized trial using its Signatera test to guide treatment escalation in advanced melanoma. The study, sponsored by NYU Langone, aims to detect molecular residual disease earlier to intensify therapy before radiographic progression.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
